aTyr Pharma to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit

Rhea-AI Summary

aTyr Pharma, a biotherapeutics company focused on innovative medicines, will present a corporate overview at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit, scheduled for September 20-23, 2021. The presentation, led by President and CEO Sanjay S. Shukla, is set for September 22, 2021, at 3:45 p.m. ET. Attendees will also have the opportunity to engage in virtual one-on-one meetings with management. A replay will be accessible on the company's website post-event.

SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Executive Officer, will present a corporate overview at the virtual Oppenheimer Fall Healthcare Life Sciences and MedTech Summit, which is being held from September 20 – 23, 2021.

The presentation will take place on Wednesday, September 22, 2021, at 3:45 p.m. ET.

In addition to the presentation, management will be available to participate in virtual one-on-one meetings with investors who are registered attendees of the conference.

Following the event, a replay of the live presentations will be available on the Investor’s section of the company’s website at www.atyrpharma.com.

About aTyr

aTyr is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is ATYR1923, a clinical-stage product candidate which binds to the Neuropilin-2 receptor and is designed to down-regulate immune engagement in inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com.

Contact:

Ashlee Dunston

Director, Investor Relations and Corporate Communications

adunston@atyrpharma.com

FAQ

What is the date and time of aTyr Pharma's presentation at the Oppenheimer Summit?

aTyr Pharma's presentation will take place on September 22, 2021, at 3:45 p.m. ET.

Who will present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit for aTyr Pharma?

Sanjay S. Shukla, M.D., M.S., the President and CEO of aTyr Pharma, will present.

Will there be an opportunity for investors to meet with aTyr Pharma management during the Summit?

Yes, management will participate in virtual one-on-one meetings with registered investors.

Where can I find a replay of aTyr Pharma's presentation after the Summit?

A replay will be available on the Investor’s section of aTyr Pharma's website.

What is aTyr Pharma's primary focus in research and development?

aTyr Pharma focuses on developing medicines based on the biology of tRNA synthetases, particularly a clinical-stage candidate called ATYR1923.